中山肛肠哪个医院好中山大便后有血怎么回事,中山哪里有电疗痔疮的,中山肛门肿包,中山最近大便出血是什么原因,中山上厕所大便有血,中山肛瘘手术需要多少钱,中山大便流血原因

BEIJING, March 10 (Xinhuanet) -- The price of preventing preterm labor is about to rise drastically in the U.S. next week.A drug for high-risk pregnant women costs about 10 to 20 dollars per injection. Next week, the price will shoot up to 1,500 dollars a dose, according to media reports Wednesday.This means the total cost during a pregnancy could be as much as 30,000 dollars.The massive increase comes after KV Pharmaceutical of St. Louis won an exclusive government license to produce the drug, known as Makena.The drug, a form of progesterone given as a weekly shot, has been made cheaply for years by unlicensed chemists.The March of Dimes and many obstetricians supported the move because it means quality will be more consistent and it will be easier to get, but none of them has anticipated the sharp price hike.Doctors and campaign groups have been caught out by the move, saying that the price hike may deter low-income women from getting the drug, leading to more premature births.

BEIJING, Feb. 7 (Xinhua) -- China on Monday called for calmness and restraint from both Cambodia and Thailand to prevent the escalation of border conflicts between the two southeast Asian countries."Both Cambodia and Thailand are China's friendly neighbors. China hopes that the two nations exercise calmness and restraint, resolve disputes through consultation, and prevent the situation from escalation," Foreign Ministry spokesman Hong Lei said.The latest fighting between Cambodian and Thai troops in their age-old territorial dispute erupted at the border region Friday afternoon and entered the fourth consecutive day Monday.

QINGDAO, Jan. 23 (Xinhua) -- Haier Group, one of the world's leading white goods and household appliance manufacturers, announced Sunday that its profit jumped 78 percent year on year in 2010.The profit hit 6.2 billion yuan (941.8 million U.S. dollars) in 2010, said Du Fangyuan, a press office coordinator of the company.Haier's sales revenue reached 135 billion yuan in 2010, up nine percent from a year earlier, Du said.The growth can be attributed to the group's successful transition of business model and product innovations, Du said.Haier Group, which is headquartered in east China's Qingdao city and has 60,000 global employees, sells its products in over 100 countries and regions around the world.

DAVOS, Switzerland, Jan. 28 (Xinhua) -- China and Switzerland formally launched bilateral talks on a free trade agreement Friday.Speaking at the opening ceremony, Chinese Commerce Minister Cheng Deming said the agreement talks between China and Switzerland have attracted huge attention and interest from the countries' leadership and business communities.Cheng expected a successful conclusion of the FTA negotiations. Cheng said a free trade agreement would enhance mutual trust between the two sides and promote economic development and closer ties between China and Switzerland.Swiss Federal Councilor Johann Schneider-Ammann expressed similar aspirations for the agreement as did his Chinese counterpart."The free trade agreement would further enhance trade and investment relations on a mutually beneficial basis, but also create many new opportunities for close exchange and cooperation," Schneider-Ammann said.China and Switzerland have seen fast-growing bilateral trade and investments for decade. In the past 10 years, China's exports to Switzerland have grown by 18 percent while Switzerland registered an even stronger 25 percent surge in exports to China.Currently, China is the largest trading partner of Switzerland in Asia, while Switzerland ranks ninth among China's trading partners in Europe.The Chinese commerce minister is leading a delegation at Davos to attend the World Economic Forum, which started Wednesday.

WASHINGTON, April 25 (Xinhua) -- A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.Working in cell lines from colorectal cancer patients, researchers found that the class of drugs called PARP inhibitors worked against tumors with mutations in the MRE11 gene.About 15 percent of all colorectal cancers have what's called microsatellite instability, a type of error in the DNA. About 82 percent of those tumors have the MRE11 gene mutation."This is a potential broader application for PARP inhibitors, beyond breast and ovarian cancer. This is a class of drug that's already shown safety in early clinical trials and now might benefit some colorectal cancer patients as well," says lead study author Eduardo Vilar-Sanchez, a hematology/oncology fellow at the university, in a statement.The study, which was published Monday in Cancer Research, also found that PARP inhibitors are even more effective when both copies of MRE11 were mutated. Each person carries two copies of each gene, which means mutations can occur in either one or both copies. The researchers suggest that PARP inhibitors could be targeted specifically to colorectal cancer patients who have two copies of the mutated gene.Researchers are planning a phase I clinical trial to look at using PARP inhibitors in colorectal cancer patients with two mutated copies of MRE11. Future trials are being considered using PARP inhibitors to prevent colorectal cancer and other cancers in people with Lynch syndrome whose tumors have this mutation.Microsatellite instability is also seen in prostate cancer and endometrial cancer, suggesting potential for PARP inhibitors to play a role in additional types of cancer as well, Vilar-Sanchez says, adding that more research is needed in these areas.